TRIPASS XR تري باس

 The human hepatic tumor cells (Bel-7204) with different concentrations of 5-Fu-PAEAPM (the content of polymeric drug (wt%): 5-Fu 25.6, PM 3.3) in the growth medium in

culture were incubated for 24h in incubator (37℃, 5% CO2). Induction of apoptosis was

confirmed by formation of apoptotic bodies and fragmentation of cellular DNA (Figure 16).

5-Fu-PAEA-PM at 18µg/ml, 36µg/ml, 62.5µg/ml and 135µg/ml concentration induced

apoptosis in about 27.6%, 43.1%, 50.7% and 62%, respectively, of human hepatic tumor cells

168 Guo-Ping Yan, Xiao-Yan Wang, Li-Li Mei

after 48h incubation. When the concentration of 5-Fu-PAEA-PM (3) increased, the

percentage of apoptosis in the human hepatic tumor cells became considerably larger. The

apoptosis experiments showed the polymeric drugs could exhibit obviously high anticancer

efficiencies and induce apoptosis in the human hepatic tumor cells (Bel-7204).

0 200 400 600 800

30

40

50

60

70

80

90

100

Viability Relative to Control (%)

Concentration (¦Ì g/mL)

 5-Fu-PAEA-PM (3)

 FT-207

Figure 15. Cytotoxicity assay of anticancer drugs in L-02 cells.

 A B

Figure 16. Induced apoptosis photo of 5-Fu-PAEA-PM in the human hepatic tumor cells. A: control

cells; B: 5-Fu-PAEA-PM (the content of polymeric drug (wt%): 5-Fu 25.6, PM 3.3) (135µg/mL).

SUMMARY

Although the liver-targeting mechanism and kinetic procedure of vitamin B6 for MRI

contrast agent and drug delivery have not described detailedly, previous researches have

demonstrated that the incorporation of pyridoxine into MRI contrast agent and anticancer

conjugates can increase their uptake by the liver, and that these molecules containing

Vitamin B6 as Liver-targeting Group in Drug Delivery 169

pyridoxine groups exhibit liver-targeting properties. Thus it is important to come to devote

greater efforts to solving these problems.

One important approach in drug design for the disease in the liver is that the drugs can be

targeted to the liver. By this method, the toxic side effects of the drugs can be suppressed and

the distribution of drugs will be changed after administered, to improve the efficiency toward

malignant cells and reduce the drugs dose. In future, the ideal drugs will be focused on the

liver-targeting property with low toxicity and side effect, low doses in vivo, and minimal cost

of procedure.

REFERENCES

[1] Van Beers, BE; Gallez, B; Pringot, J. Contrast-enhanced MR imaging of the liver.

Radiology, 1997, 203: 297-306.

[2] Wen, J; Zhuo, RX; Wang, L. Aromatic DTPA-Bis(amide) gadolinium complexes as

hepatobiliary contrast agents for magnetic resonance imaging. Chin J Magn Reson

1998, 15(3): 217-222.

[3] 3. Petre, C; Ni, Y; Marchal, G; Yu, J; Wevers, M; Lauffer, RB; Baert, AL. Detection

and characterization of primary liver cancer in rats by MS-264-enhanced MRI. Magn

Reson Med 1996, 35(4): 532-539.

[4] 4. Rocklage, SM; Cacheris, WP; Quay, SC; Hahn, FE; Raymond, KN. Magnanese (II)

N, N’–dipyridoxyl ethylenediamine-N, N’-diactate-5, 5’-bis(phosphate): synthesis and

characterization of a paramagnetic chelate for magnetic resonance imaging

enhancement. Inorg Chem 1989, 28: 477-485.

[5] Rummeny, E; Ehrenheim, C; Gehl, HB; Hamm, B; Laniado, M; Lodemann, KP;

Schmiedel, E; Steudel, A; Vogl, TG. Manganese-DPDP as a hepatobiliary contrast

agent in the magnetic resonance imaging of liver tumors: results of clinical phase II

trials in Germany including 141 patients. Invest Radiol 1991, 26: S142-145.

[6] Mitchell, DG; Alam, F. Mangafodipir Trisodium: effects on T2- and T1- weighted MR

cholangiography. J Magn Reson Imaging 1999, 9: 366-368.

[7] Wei, JF; Zhuo, RX. Studies on the novel liver-targeting MRI contrast agents containing

vitamin B6. Chin Scien Bull 1997, 42(14): 1519-1523.

[8] Yan, GP; Zhuo, RX. Research Progress of Magnetic Resonance Imaging Contrast

Agents. Chinese Science Bulletin 2001, 46 (15): 1233-1237.

[9] Yan, GP; Robinsonand, L; Hogg, P. Magnetic Resonance Imaging Contrast Agents:

overview and perspectives. Radiography, 2007 (In press).

[10] Yan, GP; Zhuo, RX; Xu, MY; Zhang, X; Li, LY; Liu, ML; Ye, CH. Hepatic targeting

macromolecular MRI contrast agents. Polym Int 2002, 51: 892-898.

[11] Yan, GP; Zhuo, RX; Xu, MY; Li, LY; Tang, YF. Liver-targeting macromolecular MRI

contrast agents. Sci China, Ser B 2001, 44 (4): 344-352.

[12] Yan, GP; Liu, ML; Li, LY. Studies on Polyaspartamide Gadolinium Complexes as

potential Magnetic Resonance Imaging Contrast Agents. Radiography, 2005, 11: 117-

122.

170 Guo-Ping Yan, Xiao-Yan Wang, Li-Li Mei

[13] Yan, GP; Bottle, SE; Zhuo, RX; Wei, L; Liu, ML; Li, LY. Evaluation on dendritic

gadolinium complexes as MRI contrast agents. J Bioact and Compatible Polym 2004,

19(6): 453-465.

[14] Yan, GP; Hu, B; Liu, ML; Li, LY. Synthesis and Evaluation of Gadolinium Complexes

Based on PAMAM as MRI Contrast Agents. Journal of Pharmacy and Pharmacology,

2005, 57(3): 351-357.

[15] Yan, GP; Bottle, SE; Zhuo, RX; Li, W; Liu, ML; Li, LY. Evaluation on Dendritic

Gadolinium Complexes as MRI Contrast Agents. Journal of Bioactive and Compatible

Polymers, 2004, 19(6): 453-465.

[16] Yan, GP; Zhuo, RX. Liver-targeting dendritic MRI contrast agents containing

pyridoxamine group. IUPAC World Polymer Congress 2002, Preprints, Part 2: 946

(2002, Beijing, China)

[17] Yan, GP; Zhuo, RX; Xu, MY. Hepatic Targeting Macromolecular MRI Contrast

Agents. Polymer International, Polymers in the Third Millennium, Oral Abstracts:

Wednesday 5 September, Session A (2001, Montpellier, France).

[18] Yan, GP; Zhuo, RX; Xu, MY. Macromolecular MRI Contrast Agents Containing

Hepatocyte-targeting Group. Transactions of the Sixth World Biomaterials Congress

Vol 3: 1447 (2000, Kamuela, Hawaii, U.S.A)

[19] Yan, GP; Zhuo, RX; Xu, MY. Synthesis, Relaxivity, MR Imaging and Biodistribution

of Macromolecular MRI Contrast Agents Containing Hepatocyte-targeting Group.

`2000 Cross-strait Polymer Learning Congress Summary: 128-131 (2000, Gaoxiong,

Taiwan).

[20] Lauterbur, PC. Image formation by induced local interactions: examples employing

nuclear magnetic resonance. Nature 1973, 242: 190-191.

[21] Gallez, B; Swartz, HM. In vivo EPR: when, how and why? NMR in Biomed 2004, 17:

223-225.

[22] Lauffer, RB. Paramagnetic metal complexes as water proton relaxation agents for NMR

imaging: theory and design. Chem Rev 1987, 87: 901-927.

[23] Nelson, KL; Runge, VM. Principles of MR contrast. In: Runge VM, editor. Contrastenhanced clinical magnetic resonance imaging. USA: The University Press of

Kentucky; 1996; 1-14.

[24] Weinmann, HJ; Brash, RC; Press, WR; Wesbey, GE. Characteristic of gadoliniumDTPA complex: a potential NMR contrast agent. Am J Radiology 1984, 142: 619-624.

[25] Mikei, K; Helm, L; Brucher, E; Merbach, A. 17O NMR study of water exchange on

Gd(DTPA)(H2O)2- and Gd(DOTA)(H2O)2- related to NMR imaging. Inorg Chem 1993,

32: 3844-3850.

[26] Zhuo, RX; Lu, ZR; Wei, JF; Yan, GP. The methods of synthesis of

polyaminocarboxylates metal complexes. Chinese Patent 1995: 95 1 19302.3.

[27] Caravan, P; Ellison, JJ; Mcmurry, TJ; Lauffer, RB. Gadolinium (III) chelates as MRI

contrast agents: structure, dynamics, and applications. Chem Rev 1999, 99: 2293-2352.

[28] Lowe, MP. MRI contrast agents: the next generation. Aust J Chem 2002, 55: 551-556.

[29] Aime, S; Dastrù, W; Crich, SG; Gianolio, E; Mainero, V. Innovative magnetic

resonance imaging diagnostic agents based on paramagnetic Gd(III) complexes.

Biopolymers (Pept Sci) 2002, 66: 419-428.

Vitamin B6 as Liver-targeting Group in Drug Delivery 171

[30] Botta, M. Second coordination sphere water molecules and relaxivity of

gadolinium(III) complexes: implication for MRI contrast agents. Eur J Inorg Chem

2000, 399-407.

[31] Wen, J; Zhuo, RX; Wang, L. Aromatic DTPA-Bis(amide) gadolinium complexes as

hepatobiliary contrast agents for magnetic resonance imaging. Chin J Magn Reson

1998, 15(3): 217-222.

[32] Weinmann, HJ; Ebert, W; Misselwitz, B; Schmitt-Willich, H. Tissue-specific MR

contrast agents. Eur J Radio 2003, 46: 33-44.

[33] Artemov, D. Molecular magnetic resonance imaging with targeted contrast agents. J

Cell Biochem 2003, 90: 518-524.

[34] Enochs, WS; Weissleder, R. Organ- and Tissue-directed MRI contrast agents. In:

Edelman RR, Hesselink JR, Zlatkin MB editors. Clinical magnetic resonance imaging.

Pennsylvania, USA: WB Saunders Company; 1996; 192-219.

[35] Lorusso, V; Arbughi, T; Tirone, P; de Haen, C. Pharmacokinetics and tissue

distribution in animals of gadobenate ion, the magnetic resonance imaging contrast

enhancing component of gadobenate dimeglumine 0.5M solution for injection

(MultiHance). J Comput Assist Tomogr 1999, 1(23): S181-194.

[36] Cavagna, F; Dapri, M; Maggioni, F; de Hahn, C; Felder, E. Gd-BOPTA/Dimeg:

experimental disease imaging. Magn Reson Med 1991, 22: 329-333.

[37] Schuhmann-Giampieri, G; Schmitt-Willich, H; Press, WR; Negishi, C; Weinmann, HJ;

Speak, U. Preclinical evaluation of Gd-EOB-DTPA as a contrast agent in MR imaging

of the hepatobiliary system. Radiology 1993, 183(1): 59-64.

[38] Cynthia, R; Rogers, J; Arias, IM. Use of an asialoglycoprotein receptor-targeted

magnetic resonance contrast agent to study changes in receptor biology during liver

regeneration endoloxemia in rats. Hepatology 1996, 23(6): 1631-1638.

[39] Fu, YJ; Zhuo, RX. Studies on D-galactose-containing DTPA bisamide gadolinium

complexes as liver-targeting MRI contrast agents. Chem J Chin Univ 1997, 18(7):

1072-1075.

[40] Moats, RA; Fraser, SE; Meade, TJ. A “smart” magnetic resonance contrast agent that

reports on specific enzymatic activity. Angew Chem Int Ed Engl 1997, 36(7): 726-728.

[41] Leveille-Webster, C; Rogers, J; Arias, IM. Use of an asialoglycoprotein receptortargeted magnetic resonance agent to study changes in receptor biology during liver

regeneration and endotoxemia in rats. Hepatology 1996, 23: 1631-1641.

[42] Zhuo, RX; Fu, YJ; Liao, J. Synthesis, relaxivity and biodistribution of novel magnetic

resonance imaging (MRI) contrast agents: polylysine (Gd-DTPA/DOTA) with pendent

galactose moieties as hepatocyte-targeting groups. Chin Chem Lett 1997, 8 (2): 157-

160.

[43] Ding, XJ; Zhuo, RX; Fu, GC. Studies on the synthesis, relaxivity and liver-targeting of

DTPA-pyridoxol ester gadolinium and manganese complexes. Chinese Science Bulletin

2001, 46 (18): 1519-1523.

[44] Ding, XJ; Zhuo, RX; Fu, GC. Studies on the synthesis, relaxivity and liver-targeting of

DTPA-pyridoxol ester gadolinium complexes. Chemical Journal of Chinese

Universities 2002, 23 (1): 49-52.

172 Guo-Ping Yan, Xiao-Yan Wang, Li-Li Mei

[45] Duarte, MG; Gil, MH; Peters, JA; Colet, JM; Elst, LV; Muller, RN; Geraldes, CFGC.

Synthesis, characterization, and relaxivity of two linear Gd(DTPA)-polymer

conjugates. Bioconjugate Chem 2001, 12: 170-177.

[46] Tόth, E; Uffelen, IV; Helm, L; Merbach, AE; Ladd, D; Briley-SæbØ, K; Kellar, E.

Gadolinium-based linear polymer with temperature-independent proton relaxivities: a

unique interplay between the water exchange and rotational contributions. Magn Reson

Chem 1998, 36: S125-134.

[47] Mohs, AM; Wang, XH; Goodrich, KC; Zong, YD; Parker, DL; Lu, ZR. PEG-gpoly(DTPA-co-L-cystine): a biodegradable macromolecular blood pool contrast agent

for MR imaging. Bioconjugate Chem 2004, 15: 1424-1430.

[48] Lu, ZR; Parker, DL; Goodrich, KC; Wang, XH; Dalle, JG; Buswell, HR. Extracellular

biodegradable macromolecular gadolinium(III) complexes for MRI. Magn Reson Med

2004, 51: 27-34.

[49] Ouyang, M; Zhuo, RX; Fu, GC. Study on synthesis and relaxivity of paramagnetic

polyester metal complexes for MRI. Ion Exchange and Adsorption 1996, 12(4): 324-

327.

[50] Bai, ZW; Zhuo, RX. The synthesis and relaxivity of polyester-amide MRI contrast

agent. Ion Exchange and Adsorption 1996, 12(4): 332-335.

[51] Brasch, RC. Rationable and applications for macromolecular Gd-based contrast agents.

Magn Reson Med 1991, 22: 282-287.

[52] Aime, S; Botta, M; Crich, SG; Giovenzana, GB; Pagliarin, R; Piccinini, M; Sisti, M;

Terreno, E. Towards MRI contrast agent of improved efficacy NMR relaxometric

investigations of the binding interaction HSA of a novel heptadentate macrocyclic

triphosphonate Gd3+-complex. J Biol Inorg Chem 1997, 2(4): 470-479.

[53] Schuhmann-Giampieri, G; Schmitt-Willich, H; Frenzel, T; Press, WR; Weinmann, HJ.

In vivo and in vitro evaluation of Gd-DTPA-polylysine as a macromolecular contrast

agent for magnetic resonance imaging. Invest Radiol 1991, 26: 969-974.

[54] Roberts, HC; Saeed, M; Roberts, TPL; Mühler, A; Brasch, RC. MRI of acute

myocardial ischemia: comparing a new contrast agent, Gd-dtpa-24-cascade-polymer,

with Gd-dtpa, J magn Reson Imaging 1999, 9: 204-208.

[55] Judd, RM; Reeder, SB; May-Newman, K. Effects of water exchange on the

measurement of myocardial perfusion using paramagnetic contrast agents. Magn Reson

Med 1999, 41: 334-342.

[56] Wen, XX; Jackson, EF; Price, RE; Kim, EE; Wu, QP; Wallace, S; Charnsangavej, C;

Gelovani, JG; Li, C. Synthesis and characterization of poly(L-glutamic acid)

gadolinium chelate: a new biodegradable MRI contrast agent. Bioconjugate Chem

2004, 15: 1408-1415.

[57] Lu, ZR; Wang, XH; Parker, DL; Goodrich, KC; Buswell, HR. Poly(L-glutamic acid)

Gd(III)-DOTA conjugate with a degradable spacer for magnetic resonance imaging.

Bioconjugate Chem 2003, 14: 715-719.

[58] Uzgiris, EE; Cline, H; Moasser, B; Grimmond, B; Amaratunga, M; Smith, JF; Goddard,

G. Conformation and structure of polymeric contrast agents for medical imaging.

Biomacromolecules 2004, 5: 54-61.

Vitamin B6 as Liver-targeting Group in Drug Delivery 173

[59] Giammona, G; Carlisi, B; Palazzo, S. α,β-Poly (N-hydroxyethyl)- DL-aspartamide with

derivatives of carboxylic acids. J Polym Sci Polym Chem 1987, 25: 2813-2818.

[60] Giammona, G; Carlisi, B; Cavallaro, G. Calorimetric investigation of the interaction

betweenα,β-Poly (N-hydroxyethyl)-DL-aspartamide and surfactants. Int J Pharm 1990,

64: 239-242.

[61] Giammona, G; Carlisi, B; Pitarresi, G. Hydrophilic and hydropholic polymeric

derivatives of antiinflammatory agents such as Alclofenac, Ketoprofen and Ibuprofen. J

Bioact Compatible polym 1991, 6: 129-141.

[62] Giammona, G; Carlisi, B; Pitarresi, G. Water-soluble copolymers of an antiviral agent:

synthesis and their interaction with a biomembrane model. J Control Release 1992, 22:

197-204.

[63] Giammona, G; Cavallaro, G; Fontana, G. Coupling of the antiviral agent zidovudine to

polyaspartamide and in vitro drug release studies. J Control Release 1998, 54: 321-331.

[64] Yan, GP; Zhuo, RX; Zheng, CY. Study on the Anticancer Drug 5-Fluorouracilconjugated Polyaspartamides Containing Hepatocyte-targeting Group. Journal of

Bioactive and Compatible Polymers 2001, 16 (4): 277-293.

[65] Yan, GP; Liu, ML; Li, LY. Studies on Polyaspartamide Gadolinium Complexes

Containing Sulfadiazine Groups as MRI Contrast Agents. Bioconjugate Chemistry

2005, 16: 967-971.

[66] Yan, GP; Zhuo, RX; Yang, YH; Xu, MY; Li, LY; Ye, ZH. Tumor-selective

Macromolecular MRI Contrast Agents. Journal of Bioactive and Compatible Polymers

2002, 17 (2): 139-151.

[67] Esfand, R; Tomalia, DA. Poly(amidoamine) (PAMAM) dendrimers: from biomimicry

to drug delivery and biomedical applications. Drug Discovery Today 2001, 6(8): 427-

436.

[68] Kobayshi, H; Kawamoto, S; Jo, SK; Bryant, HL; Brechbiel, MW; Star, RA.

Macromolecular MRI contrast agents with small dendrimers: pharmacokinetic

differences between sizes and cores. Bioconjugate Chem 2003, 14: 388-394.

[69] Margerum, LD; Campion, BK; Koo, M; Shargill, N; Lai, JJ; Marumoto, A; Sontum,

PC. Gadolinium (III) DO3A macrocycles and polyethylene glycol coupled to

dendrimers effect of molecular weight on physical and biological properties of

macromolecular magnetic resonance imaging contrast agents. Journal of Alloys and

Compounds 1997, 249:185-190.

[70] Yokoyama, M; Inoue, S. Preparation of adriamycin-conjugated poly(ethylene glycol)-

poly(aspartic acid) block copolymer. Macromol Chem Rapid Commun 1987, 8: 431-

435.

[71] Patri, AK; Majoros, IJ; Baker, JR. Dendritic polymer macromolecular carriers for drug

delivery. Current Opinion in Chemical Biology 2002, 6: 466-471.

[72] Fischer, M; Vögtle, F. Dendrimers: from design to application—a progress report.

Angew Chem Int Ed 1999, 38: 884-905.

[73] Wiener, EC; Brechbiel, MW; Brothers, H; Magin, RL; Gansow, OA; Tomalia, DA;

Lauterbur, PC. Dendrimer-based metal chelates: a new class of magnetic resonance

imaging contrast agents. Magn Reson Med 1994, 31: 1-8.

174 Guo-Ping Yan, Xiao-Yan Wang, Li-Li Mei

[74] Stiriba, SE; Frey, H; Haag, R. Dendritic polymers in biomedical applications: from

potential to clinical use in diagnostics and therapy. Angew Chem Int Ed 2002,

41(8):1329-1334.

[75] Neerman, MF; Zhang, W; Parrish, AR; Simanek, EE. In vitro and in vivo evaluation of

a melamine dendrimer as a vehicle for drug delivery. Int J Pharmac 2004, 281: 129-

132.

[76] Wiener, EC; Auteri, FP; Chen, JW; Brechbiel, MW; Gansow, OA; Schneider, DS;

Belford, RL; Clarkson, RB; Lauterbur, PC. Molecular dynamics of ion-chelate

complexes attached to dendrimers. J Am Chem Soc 1996, 118: 7774-7782.

[77] Nicolle, GM; Toth, E; Schmitt-Willich, H; Raduchel, B; Merbach, AE. The Impact of

Rigidity and Water Exchange on the Relaxivity of a Dendritic MRI Contrast Agent.

Chem Eur J 2002, 8(5): 1040-1048.

[78] Bryant, LH; Brechbiel, MW; Wu, CC; Bulte, JWM; Herynek, V; Frank, JA. Synthesis

and Relaxometry of High-Generation (G=5, 7, 9, and 10) PAMAM Dendrimer-DOTAGadolinium Chelates. J Magn Reson Imaging 1999, 9: 348-352.

[79] Stiriba, SE; Frey, H; Haag, R. Dendritic polymers in biomedical applications: from

potential to clinical in diagnostics and therapy. Angew Chem Int Ed, 2002, 41(8): 1329-

1334.

[80] Kobayashi, H; Jo, SK; Kawamoto, S; Yasuda, H; Hu, XZ; Knopp, MV; Brechbiel,

MW; Choyke, PL; Star, RA. Polyamine dendrimer-based MRI contrast agents for

functional kidney imaging to diagnose acute renal failure. J Magn Reson Imaging 2004,

20: 512-518.

[81] Langer, R. Polymer-controlled drug delivery systems. Acc Chem Res 1993, 26: 537-

542.

[82] Nishikawa, M; Takakura, Y. Pharmacokinetic evalution of polymeric carriers. Adv

Drug Del Rev 1996, 21: 135-155.

[83] Sezaki, H; Takakura, Y; Hashida, M. Souble macromolecular carriers for the delivery

of antitumor drugs. Adv Drug Del Rev 1989, 3: 247-266.

In: Vitamin B: New Research ISBN: 978-1-60021-782-1

Editor: C. M. Elliot, pp. 175-191 © 2008 Nova Science Publishers, Inc.

Chapter X

THE ROLE AND STATUS OF VITAMIN B12:

NEED FOR CLINICAL

REEVALUATION AND CHANGE

Ilia Volkov∗ , Inna Rudoy and Yan Press

Department of Family Medicine, Faculty of Health Sciences, Ben-Gurion University of

the Negev, Beer-Sheva, Israel.

ABSTRACT

Vitamin B12 plays a functional role in a variety of organs and body systems and the

list of these organs and body systems is growing. It affects the peripheral and central

nervous systems, bone marrow, skin and mucous membranes, bones, and vessels, as well

as the normal development of children. Vitamin B12 (cobalamin) is unique among all the

vitamins in that it contains not only a complex organic molecule but also an essential

trace element, cobalt. Vitamin B12 plays an important role in DNA synthesis and has

important immunomodulatory and neurotrophic effects. According to our “working

hypothesis” a vitamin B12 has some unique, but still unrecognized functions.

Multifunctional systems in the human body need to maintain homeostasis. Man is an

ideal example of a system that constantly aspires to attain optimal regulation, even under

the stress of severe pathology. We assume that there are universal, interchangeable (as

required) propose that one of these substances is vitamin B12.Why vitamin B12? It is

possible that even when the serum cobalamin level is normal, treatment with vitamin B12

can correct defects caused by other biologically active substances. In our studies this has

been proved successful in the treatment of recurrent aphthous stomatitis with vitamin B12

(irrespective of its blood level!). We call this phenomenon the “Master Key” effect.

Vitamin B12 deficiency is a common problem that affects the general population.

Early detection of vitamin B12 deficiency is clinically important, and there is evidence

∗

 Correspondence concerning this article should be addressed to Dr. Ilia Volkov, Lea Imenu St. 59/2, Beer-Sheva,

84514, Israel. Tel: 972-8-6431530; Cell phone: 972-54-7829623; Fax: 972-8-6413135; E-mail:

r0019@zahav.net.il.

176 Ilia Volkov, Inna Rudoy and Yan Press

that such deficiency occurs more frequently than would be expected. Vitamin B12

deficiency can occur in individuals with dietary patterns that exclude animal foods and

patients who are unable to absorb vitamin B12 in food. In addition there is an overall

tendency to avoid eating those foods which are high in Vitamin B12, such as beef,

because of the relationship between meat, cholesterol and cardiovascular diseases. Also

there is a tendency, particularly among the younger generation, to be vegetarians for

ideological motives. Changes in life style among segments of the population with high

socioeconomic level, on one hand, and the existence of poverty, on the other, are two

main factors in the decreasing consumption of animal products, particularly red meat.

Thus, there is a decrease in the level of vitamin B12 in general population, and as a

consequence, an increase in pathology due to vitamin B12 deficiency (such as

neurological and hematological disorders). If future research will corroborate the

relationship between vitamin B12 and homocystein, we may observe an increase in

cardiovascular disease as well. In lieu of these developments and in order to prevent

serious health problems, vitamin B12 fortification should be seriously considered and

discussed.

BACKGROUND

Vitamin B12 plays a functional role in a variety of organs and body systems and the list of

these organs and body systems is growing. It affects the peripheral and central nervous

systems, bone marrow, skin and mucous membranes, bones, and vessels, as well as the

normal development of children. Vitamin B12 (cobalamin) is unique among all the vitamins

in that it contains not only a complex organic molecule but also an essential trace element,

cobalt. Vitamin B12 plays an important role in DNA synthesis and has important

immunomodulatory and neurotrophic effects. According to our “working hypothesis” a

vitamin B12 has some unique, but still unrecognized functions.

Multifunctional systems in the human body need to maintain homeostasis. Man is an

ideal example of a system that constantly aspires to attain optimal regulation, even under the

stress of severe pathology. We assume that there are universal, interchangeable (as required)

propose that one of these substances is vitamin B12.Why vitamin B12? It is possible that even

when the serum cobalamin level is normal, treatment with vitamin B12 can correct defects

caused by other biologically active substances. In our studies this has been proved successful

in the treatment of recurrent aphthous stomatitis with vitamin B12 (irrespective of its blood

level!). We call this phenomenon the “Master Key” effect [1].

Vitamin B12 deficiency is a common problem. Early detection of vitamin B12 deficiency

is essential in order to prescribe opportune treatment, and there is evidence that such

deficiency occurs more frequently than would be expected. Vitamin B12 deficiency can occur

in individuals with dietary patterns that exclude animal food products and patients who are

unable to absorb vitamin B12. Persons with B12 deficiency may be asymptomatic, but in

patients presenting with myelopathy, cognitive decline, neuropathy, psychiatric disturbances

or specific hematological signs and symptoms, B12 deficiency should be suspected. There are

no generally accepted guidelines for the definition, diagnosis, treatment, and follow-up of

cobalamin deficiency. Total serum vitamin B12 may not reliably indicate vitamin B12 status.

Probability of "functional" vitamin B12 deficiency decreases upon increasing the blood level

The Role and Status of Vitamin B12: Need for Clinical Reevaluation and Change 177

of vitamin B12. To increase specifity and sensitivity in diagnosing vitamin B12 deficiency, the

concept of measuring homocystein (HCY), methylmalonic acid (MMA), holotranscobalamin

II (holoTC),- a sub-fraction of vitamin B12, has aroused great interest. HoloTC, as a

biologically active vitamin B12 fraction, promotes uptake of its vitamin B12 by all cells [2].

However, diagnostic algorithms using vitamin B12, MMA, and HCY measurements reflect

studies in some academic centers, and their negative predictive values have not been

established. Therefore, this problem remains controversial [3].

We will attempt to demonstrate vitamin B12 critical roles by surveying and analyzing

available reports, as well as reporting our own clinical experience.